Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Moleculin Biotech, Inc. (MBRX) had Stock-Based Compensation of $0.48M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-6.44M |
|
-- |
|
-- |
|
$5.94M |
|
$-5.94M |
|
$-0.49M |
|
$-6.44M |
|
$-6.44M |
|
$-6.44M |
|
$-6.44M |
|
$-6.44M |
|
$-6.44M |
|
$-5.94M |
|
$-5.91M |
|
9.34M |
|
9.34M |
|
$-0.69 |
|
$-0.69 |
|
| Balance Sheet Financials | |
$9.34M |
|
$0.13M |
|
$11.67M |
|
$21.01M |
|
$6.90M |
|
-- |
|
$14.07M |
|
$20.97M |
|
$0.04M |
|
$-11.11M |
|
$0.04M |
|
14.13M |
|
| Cash Flow Statement Financials | |
$-4.56M |
|
-- |
|
$8.00M |
|
$4.28M |
|
$7.72M |
|
$3.44M |
|
|
Stock-Based Compensation |
$0.48M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.35 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-4.56M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-15317.58% |
|
57.95% |
|
-30.63% |
|
-15323.81% |
|
$0.00 |
|
$-0.49 |
|
$-0.49 |
|